DR. SUMATHI KANNIAPPAN
Consultant - Diabetes & Endocrinology
MBBS,FEDM,FACE
Book an appointment
Select Branch
Select Speciality
No slots are available. Please fill the below form to request a callback.
OR
For walk-in Accommodation please dial
1800 2122
Dr K Sumathi is a senior Endocrinologist in Hebbal Bangalore. She has an extensive experience of over 20 years. She holds an MBBS from Bangalore University and also specialised in Endocrinology. She has interests in Preventive Medicine and Cardio Vascular Health, Maturity onset Diabetes of the young. Gestational diabetes, women health, obesity, PCOs and Pre conception care. Inpatient diabetes management, hormonal imbalances with disorders related to endocrine glands, Pituitary , Thyroid, Adrenals & Gonads, Bone disorders. ▪Visiting Clinician Programme in Department of Endocrinology at Mayo Clinic, Rochester, Minnesota USA
▪AACE 24th Annual Scientific and Clinical Congress, Nashville, Tennessee, USA
▪ADA 75th Scientific Sessions Boston, MA, USA
▪Asia-Pacific Pediatric Endocrinology Society APPES Scientific Conference, Bali, Indonesia, 2012
▪Asia Oceania Thyroid Association Congress 2014, Kochi India, 2014
▪Attended International Clinical Research Meeting at London UK Conducted by Novartis, 2009 ▪A multi-center, double-blind, placebo-controlled, randomized compare the effect of a subcutaneous canakinumab administration to placebo in patients with Impaired Glucose Tolerance or patients with Type 2 Diabetes treated with differing baseline diabetes therapies [Novartis], 2009
▪Attended International Clinical Research Meeting at Prague, Czechoslovakia, 2010
▪A Multicenter, Randomized, Double Blind, Placebo- Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infraction or Ischaemic Stroke in Patients with Type 2 Diabetes [SAVOR-TIMI at Prague, Czechoslovakia, 2010
▪Attended International Clinical Research Meeting at Singapore City, Singapore, 2010
Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of JNJ-28431754(Canagliflozin) Compared with Sitagliptin and Placebo in the Treatment of Subjects with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin Monotherapy
